Pharmacogenetic association study of 30 genes with phenobarbital drug response in epileptic dogs

Pharmacogenetics and Genomics

Volumn 19, Issue 12, 2009, Pages 911-922

  Kennerly, Erin M ^a   Idaghdour, Youssef ^a   Olby, Natasha J ^b   Munana, Karen R ^b   Gibson, Greg ^a,c  

^a Gardner Hall ^*  (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Canine epilepsy; Drug response; Epoxide hydrolase; GABRA2; KCNQ3; Pharmacogenetics; Phenobarbital; SCN2A2

Indexed keywords

PHENOBARBITAL; POTASSIUM CHANNEL KCNQ3;

ABCC4 GENE; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREED DIFFERENCE; CONTROLLED STUDY; DOG; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSPORT; EPILEPSY; EPOX HYD GENE; FEMALE; GABRA2 GENE; GENE; GENETIC ASSOCIATION; GENOTYPE; KCNQ3 GENE; MALE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SNC2A2 GENE;

ANIMALS; ANTICONVULSANTS; CASE-CONTROL STUDIES; DOG DISEASES; DOGS; DRUG RESISTANCE; EPILEPSY; PHARMACOGENETICS; PHENOBARBITAL; POLYMORPHISM, SINGLE NUCLEOTIDE;

CANIS FAMILIARIS;

EID: 73949160744     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283307cba     Document Type: Article

References (56)

1. O'Brien D. Pathogenesis of idiopathic epilepsy. In: Proceedings of the American College of Veterinary Internal Medicine Annual Forum, 2003 (Lakewood, Colorado) pp. 404-406.
2. Podell M, Fenner WR, Powers JD. Seizure classification in dogs from a nonreferral-based population. J Am Vet Med Assoc 1995; 206:1721-1728.
3. Berendt M, Gram L. Epilepsy and seizure classification in 63 dogs: a reappraisal of veterinary epilepsy terminology. J Vet Intern Med 1999; 13:14-20.
4. Licht B, Licht M, Harper K, Lin S, Curtin J, Hyson L, Willard K. Clinical presentations of naturally occurring canine seizures: similarities to human seizures. Epilepsy Behav 2002; 3:460-470.
5. Chandler K. Canine epilepsy: what we can learn from human seizure disorders? Vet J 2006; 172:207-217.
6. Benet L, Kroetz D, Sheiner L. Pharamacokinetics: dynamics of drug absorption, distribution, and elimination. Pharmacol Basic Ther 1996; 9:3-28.
7. Dowling P. Management of canine epilepsy with phenobarbital and potassium bromide. Can Vet J 1994; 35:724-725.
8. Schwartz-Porsche D, Loscher W, Frey H. Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. J Vet Pharmacol Ther 1985; 8:113-119.
9. Cramer JA, French J. Quantitative assessment of seizure severity for clinical trials: a review of approaches to seizure components. Epilepsia 2001; 42:119-129.
10. Trepanier LA, Van Schoick A, Schwark WS, Carrillo J. Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996). J Am Vet Med Assoc 1998; 213:1449-1453.
11. Poddell M, Fenner W. Bromide therapy in refractory canine idiopathic epilepsy. J Vet Intern Med 1993; 7:318-327.
12. Gaskill C, Miller L, Mattoon S, Hoffmann W, Burton S, Gelens H, et al. Liver histopathology and liver and serum alanine aminotransferase and alkaline phosphatase activities in epileptic dogs receiving phenobarbital. Vet Pathol 2005; 42:147-160.
13. Jacobs G, Calvert C, Kaufman A. Neutropenia and thrombocytopenia in three dogs treated with anticonvulsants. JAMA 1998; 212:681-684.
14. Patterson E, Mickelson J, Da Y, Roberts M, McVey A, O'Brien D, et al. Clinical characteristics an inheritance of idiopathic epilepsy in Vizslas. J Am Vet Med Assoc 2003; 17:319-325.
15. Patterson E, Armstrong P, O'Brien D, Roberts M, Johnson G, Mickelson J. Clinical description and mode of inheritance of idiopathic epilepsy in English Springer Spaniels. J Am Vet Med Assoc 2005; 226:54-58.
16. Jaggy A, Faissler D, Gaillard C, Srenk P, Graber H. Genetic aspects of idiopathic epilepsy in Labrador retrievers. J Small Anim Pract 1998; 39:275-280.
17. Casal M, Munuve R, Janus M, Warner P, Henthorn P. Epilepsy in Irish wolfhounds. J Intern Vet Med 2006; 20:131-135.
18. Tate S, Depondt C, Sisodiya S, Cavalleri G, Schorge S, Soranzo A, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A 2005; 102:5507-5512.
19. Neff M, Robertson K, Wong A, Safra N, Broman K, Slatkin M, et al. Breed distribution and history of canine mdrl-l Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci USA 2004; 101:11725-11730.
20. Lindblad-Toh K, Wade C, Mikkelsen T, Karlsson E, Jaffe D, Kamal M, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005; 438:803-819.
21. Meldrum B, Rogawski M. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007; 4:18-61.
22. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955; 11:375-386.
23. Sasieni P. From genotype to genes: doubling the sample size. Biometrics 1997; 53:1253-1261.
24. Nielsen D, Weir B. A classical setting for associations between markers and loci affecting quantitative traits. Genet Res 1999; 74:271-277.
25. Pritchard J, Stephens M, Rosenberg N, Donnelly P. Association mapping in structured populations. Am J Hum Genet 2000; 67:170-181.
26. Faulsh D, Stephens M, Pritchard J. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 2003; 164:1567-1587.
27. Parker H, Kim L, Sutter N, Carlson S, Lorentzen T, Malek D, et al. Genetic structure of the purebred domestic dog. Science 2004; 304:1160-1164.
28. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65:220-228.
29. Purcell S, Cherny SS, Sham PC. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19:149-150.
30. Sutter N, Eberle M, Parker H, Pullar B, Kirkness E, Kruglyak L, et al. Extensive and breed-specific linkage disequilibrium in Canis familiaris. Genome Res 2004; 14:2388-2396.
31. Patterson D, Haskins M, Jezyk P, Giger U, Meyers-Wallen V, Aguirre G, et al. Research on genetic diseases: reciprocal benefits to animals and man. J Am Vet Med Assoc 1988; 193:1131-1144.
32. Fischer J, Bachmann L, Jaeschke R. A reader's guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003; 29:1043-1051.
33. Greiner M, Pfeiffer D, Smith R. Principles and practical application of the receiver-operating characteristics analysis for diagnostic test. Prev Vet Med 2000; 45:23-41.
34. https://www.broadinstitute.org/science/projects/mammals-models/dog/ canine-array/canine-array-faq
35. Sutter NB, Bustamante CD, Chase K, Gray M, Zhao K, Zhu L, et al. A single IGF1 allele is a major determinant of small size in dogs. Science 2007; 316:112-115.
36. Karlsson EK, Baranowska I, Wade CM, Salmon-Hillbertz N, Zody MC, Anderson N, et al. Efficient mapping of Mendelian traits in dogs through genome-wide association. Nat Genet 2007; 39:1321-1328.
37. Schmidt D, Loscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005; 46:858-877. (Pubitemid 40847354)
38. Armijo J, Shushtarian M, Valdizan E, Cuadrado A, de las Cuevas I, Adin J. Ion channels and epilepsy. Curr Pharm Des 2005; 11:1975-2003.
39. Wallace R, Wang D, Singh R, Scheffer I, George A, Phillips H, et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na( + )-channel beta-1 subunit gene SCN1B. Nat Genet 1998; 19:366-370.
40. Sugawara T, Mazaki-Miyazaki E, Ito M, Nagafuji H, Fukuma G, Mitsudome A, et al. Na-v-1.1 mutations cause febrile seizures associated with afebrile partial seizures. Neurology 2001; 57:703-705.
41. NeuBauer B, Waldegger S, Heinzinger J, Hahn A, Kurlemann G, Fiedler B, et al. KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromes. Neurology 2008; 72:177-183.
42. Volk H, Arabadzisz D, Fritschy J, Brandt C, Bethmann K, Loscher W. Anti-epileptic drug-resistant rats differ from drug-responsive rats in hippocampal neurodegeneration and GABAA receptor ligand binding in a model of temporal lobe epilepsy. Neurobiol Dis 2006; 21:633-646.
43. Bethmann K, Fritschy J-M, Brandt C, Loscher W. Antiepileptic drug resistant rats differ from drug responsive rats in GABAA receptor subunit expression in a model of temporal lobe epilepsy. Neurobiol Dis 2008; 31:169-187.
44. Volk H, Loscher W. Multidrug resistance in epilepsy: rats with drug resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005; 128:1358-1368.
45. Brandt C, Bethmann K, Gasten A, Loscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof of principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 2006; 24:202-211.
46. Farnback G. Serum concentrations and efficacy of phenytoin, phenobarbital, and primidone in canine epilepsy. J Am Vet Med Assoc 1984; 184: 1117-1120.
47. Knowles K. Idiopathic epilepsy. Clin Tech Small Anim Pract 1998; 13:144-151.
48. Klutz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2007; 46:271-279.
49. Tenmizu D, Endo Y, Noguchi K, Kamimura H. Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion. Xenobiotica 2004; 34:835-846.
50. Waxman D, Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 1992; 281:577-592.
51. Mochizuki M, Shimizu S, Kitazawa T, Umeshita K, Goto K, Kamata T, et al. Blood coagulation-related parameter changes in Sprague-Dawley (SD) rats treated with phenobarbital (PB) and PB plus vitamin K. J Toxicol Sci 2008; 33:307-314.
52. Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H, Almog S. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome p450 2C9. Clin Pharmacol Ther 2005; 77:365-372.
53. Anderson G. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004; 63:S3-S8.
54. Goto S, Seo T, Murata T, Nakada N, Ueda N, Ishitsu T, et al. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther Drug Monit 2007; 29:118-121.
55. Graham R, Tyler L, Krol W, Silver I, Webster L, Clark P, et al. Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes. J Biochem Mol Toxicol 2006; 20:69-78.
56. Chang Y, Mellor D, Anderson T. Idiopathic epilepsy in dogs: owners' perspectives on management with phenobarbitone and/or potassium bromide. J Small Anim Pract 2006; 47:574-581.